FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from XXXX .

@entity1 @entity137 @entity14
BACKGROUND: In @entity1 with @entity14 ( @entity14 ) R0 resection significantly improves overall survival (OS). METHODS: In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in @entity1 with non-optimally resectable @entity14 . @entity1 received six cycles of FOLFOX6+ five of bevacizumab. @entity1 not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment. RESULTS: From September 2005 to July 2009, 21 @entity1 were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one @entity1 died from @entity137 before surgery. Thirteen @entity1 underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six @entity1 (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. @entity1 achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001). CONCLUSIONS: FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.
